These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25592633)

  • 1. Sunitinib in thymic carcinoma: enigmas still unresolved.
    Marx A; Weis CA
    Lancet Oncol; 2015 Feb; 16(2):124-5. PubMed ID: 25592633
    [No Abstract]   [Full Text] [Related]  

  • 2. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
    Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
    Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When a thymic carcinoma "becomes" a GIST.
    Rossi V; Donini M; Sergio P; Passalacqua R; Rossi G; Buti S
    Lung Cancer; 2013 Apr; 80(1):106-8. PubMed ID: 23375402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.
    Ströbel P; Bargou R; Wolff A; Spitzer D; Manegold C; Dimitrakopoulou-Strauss A; Strauss L; Sauer C; Mayer F; Hohenberger P; Marx A
    Br J Cancer; 2010 Jul; 103(2):196-200. PubMed ID: 20571495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib effective for rare thymus cancer.
    Cancer Discov; 2015 Apr; 5(4):340. PubMed ID: 25680712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature.
    Daste A; Gross-Goupil M; Quivy A; François L; Bernhard JC; Ravaud A
    Clin Genitourin Cancer; 2016 Oct; 14(5):e525-e527. PubMed ID: 27185091
    [No Abstract]   [Full Text] [Related]  

  • 7. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Bajetta E; Guadalupi V; Procopio G
    J Clin Oncol; 2009 Jan; 27(2):319-20; author reply 320. PubMed ID: 19064950
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting neuroendocrine tumor: mixing standard options with novel therapies.
    Raymond E; Dreyer C; Faivre S
    Target Oncol; 2012 Sep; 7(3):151-2. PubMed ID: 22918794
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors.
    Spiegel AM; Libutti SK
    Nat Rev Clin Oncol; 2011 May; 8(5):258-9. PubMed ID: 21448150
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of sunitinib in a 30-year-old woman with pancreatic neuroendocrine tumors associated with Von Hippel-Lindau syndrome.
    Wang W; Jiang CY; Wang HW
    J Clin Gastroenterol; 2015 Jan; 49(1):89-90. PubMed ID: 24921213
    [No Abstract]   [Full Text] [Related]  

  • 11. Sunitinib for advanced pancreatic neuroendocrine tumors.
    Hubner RA; Valle JW
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1817-27. PubMed ID: 22117148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy for thymic carcinoma].
    Okuma Y
    Gan To Kagaku Ryoho; 2012 May; 39(5):702-7. PubMed ID: 22584319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in pancreatic neuroendocrine tumor treatment.
    Castellano D; Grande E; Barriuso J
    N Engl J Med; 2011 May; 364(19):1872-3; author reply 1873-4. PubMed ID: 21561356
    [No Abstract]   [Full Text] [Related]  

  • 14. [Recent progress in the molecular-targeting treatment of neuroendocrine tumors].
    Unno M
    Nihon Shokakibyo Gakkai Zasshi; 2010 Mar; 107(3):392-5. PubMed ID: 20203442
    [No Abstract]   [Full Text] [Related]  

  • 15. Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.
    Remon J; Girard N; Mazieres J; Dansin E; Pichon E; Greillier L; Dubos C; Lindsay CR; Besse B
    Lung Cancer; 2016 Jul; 97():99-104. PubMed ID: 27237035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in pancreatic neuroendocrine tumor treatment.
    van der Veldt AA; Kleijn SA
    N Engl J Med; 2011 May; 364(19):1873; author reply 1873-5. PubMed ID: 21561355
    [No Abstract]   [Full Text] [Related]  

  • 17. Images in clinical medicine. Sunitinib-associated hair depigmentation.
    Brzezniak C; Szabo E
    N Engl J Med; 2014 Apr; 370(17):e27. PubMed ID: 24758639
    [No Abstract]   [Full Text] [Related]  

  • 18. [A case report of a well-differentiated neuroendocrine tumor in which sunitinib treatment resulted in stable disease].
    Tamaru S; Mizuno T; Oda H; Sugawara Y; Saito K; Yamashita Y; Kageyama S; Uchida K; Imai H; Matsuoka N; Katayama N
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1237-40. PubMed ID: 24047788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New target therapies for patients with neuroendocrine tumors of the pancreas.
    Baltogiannis G; Katsios C; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2011 Oct; 5(5):563-6. PubMed ID: 21910571
    [No Abstract]   [Full Text] [Related]  

  • 20. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
    Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
    Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.